Zymar

(gatifloxacin)

ApprovedSmall molecule

AbbVie

Zymar is one of 77 small molecule programs targeting Bacterial Conjunctivitis. It is currently in Approved.

Indications

Total Trials

Active Trials

Competitors

FDA Applications

NDA/BLA/ANDA regulatory filings

Pipeline

Status by Indication[3][1]

Indication

Bacterial ConjunctivitisActive, not recruiting

Pulmonary TuberculosisActive, not recruiting

CataractActive, not recruiting

Bacterial ConjunctivitisPhase 3

Active, not recruiting

Pulmonary TuberculosisPhase 1/Phase 2

Active, not recruiting

CataractApproved

Active, not recruiting

Competition

Competitive Landscape

219 competitors in Cataract

#DrugCompanyPhaseTrials

Pred Forte

Novartis

Phase 3

6 2

Zymar

AbbVie

Approved

2 3

Toradol

JJavelin Pharmaceuticals

Phase 3

4 4

Floxin

WWim Janssens

Phase 3

1 5

Tetracaine Hydrochloride

BBausch Health Americas, Inc.

Phase 3

1 6

Phenylephrine Hcl

Bayer

Phase 3

1 7

Zolymbus

AbbVie

Preclinical

—8

Neurontin

VViatris Specialty LLC

Preclinical

3 9

Xylocaine

MMEDRx USA, Inc.

Preclinical

1 10

Bactroban

PPadagis LLC

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Concentration2 trials

Assessment of the Concentrations of Besifloxacin, Moxifloxacin, or Gatifloxacin in the Aqueous Humor of Subjects

Completed·BBausch & Lomb Incorporated·Phase 1·NCT00824070·105 enrolled

Concentration of Besifloxacin, Gatifloxacin, and Moxifloxacin in Human Conjunctiva After Topical Instillation

Completed·BBausch & Lomb Incorporated·Phase 1·NCT00905762·119 enrolled

Cataract2 trials

Therapeutic Variables in Cataract Surgery

Completed·IInnovative Medical·Phase 4·NCT00407017

Preoperative Topical Gatifloxacin on Anterior Chamber Cultures After Cataract Surgery

Withdrawn·QQueen's University·N/A·NCT00335231

Bacterial Conjunctivitis2 trials

Besifloxacin Ophthalmic Suspension Verses Gatifloxacin Ophthalmic Solution in Neonates With Bacterial Conjunctivitis

Terminated·BBausch & Lomb Incorporated·Phase 3·NCT01330355·33 enrolled

A Study to Evaluate the Safety and Efficacy of Gatifloxacin for the Treatment of Bacterial Conjunctivitis

Completed· AbbVie logo

AbbVie·Phase 4·NCT00464438·171 enrolled

Enteric Fever1 trial

Gatifloxacin Versus Ceftriaxone in the Treatment of Enteric Fever

Completed·OOxford University Clinical Research Unit, Vietnam·Phase 4·NCT01421693·300 enrolled

Treatment1 trial

Prophylactic Treatment: Lessdrops™ vs Standard Drops Regimen

Completed·CCarolina Eyecare Physicians, LLC·Phase 4·NCT03578276·35 enrolled

3 more indications

Pulmonary Tuberculosis1 trial

Early Bactericidal Activity of Linezolid, Gatifloxacin, Levofloxacin, Isoniazid (INH) and Moxifloxacin in HIV Negative Adults With Initial Episodes of Sputum Smear-Positive Pulmonary Tuberculosis

Completed·NNational Institute of Allergy and Infectious Diseases (NIAID)·Phase 1/2·NCT00396084·70 enrolled

Fluoroquinolone1 trial

Comparison of the Effect of 4th Generation Fluoroquinolones, Gatifloxacin and Moxifloxacin, on Epithelial Healing Following Photorefractive Keratectomy (PRK), A Substudy of: Initial Evaluation of Excimer Laser Keratorefractive Surgery in U.S. Army Personnel (WU # 2335-99)

Completed·WWalter Reed Army Medical Center·N/A·NCT00414011·40 enrolled

Antibiotics1 trial

Topical Antibiotics and Intravitreous Injections

Completed·SStanford University·Phase 4·NCT00410891·129 enrolled

Regulatory

FDA Approval Timeline[4]

Mar 28, 2003

ZYMAR

NDA NDA021493

May 18, 2010

ZYMAXID

NDA NDA022548

Sources

References

[1]
ClinicalTrials.gov — 11 trial records for gatifloxacin. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — gatifloxacin compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for gatifloxacin. EMBL-EBI & Wellcome Sanger Institute.
[4]
OpenFDA — FDA approval records (NDA NDA022548). U.S. Food & Drug Administration.
[5]
SEC EDGAR — AbbVie company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Approved[1]
Company: AbbVie

Zymar

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Concentration2 trials

Cataract2 trials

Bacterial Conjunctivitis2 trials

Enteric Fever1 trial

Treatment1 trial

Pulmonary Tuberculosis1 trial

Fluoroquinolone1 trial

Antibiotics1 trial

FDA Approval Timeline[4]

References

Drug Info

Quick Facts

Related News